Special Issue

Infectious Disease Immunotherapy Research

Message from the Guest Editor

The ability to modulate the immune response has received a great deal of research focus recently. Examples include the use of adjuvants to increase immunogenicity of vaccines, nanoparticles to deliver SARS-CoV-2 mRNA vaccines, the use of recombinant cytokines to boost antiviral responses, and checkpoint inhibitors to enhance immune responses against infectious agents in immunocompromised individuals. Other factors can be used to control and overexuberant or misguided immune response. Examples include the use of cytokine-neutralizing antibodies, steroids, and inhibitors of targeted pathways (e.g., inflammasomes, toll-like receptors, cytokine receptors). Researchers are now well positioned to utilize these methods to better understand the mechanisms behind maintaining a fine balance between controlling pathogens and limiting collateral damage. This will allow for the more rapid development of immunomodulatory therapeutics that will advance human health. This Special Issue of *Vaccines* is dedicated to highlighting studies that focus on modulating the immune response against infectious agents.

Guest Editor

Dr. Ravi S. Misra

Division of Neonatology, Department of Pediatrics, University of Rochester Medical Center, Rochester, NY 14642, USA

Deadline for manuscript submissions

closed (31 October 2023)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/69336

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

MDPI